Blueprint Medicines to Present at Upcoming Investor Conferences
05/25/2021 - 08:00 AM
CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.
Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 p.m. ET . Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 8:50 a.m. ET . JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 1:00 p.m. ET .A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe , and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com Twitter LinkedIn
http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-301298404.html
SOURCE Blueprint Medicines Corporation
BPMC Rankings
#1628 Ranked by Stock Gains
BPMC Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About BPMC
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
